Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BIO-DrIM

Financiado

Cerrado

Personalized minimization of immunosuppression after solid organ transplantation...

Personalized minimization of immunosuppression after solid organ transplantation by biomarker driven stratification of patients to improve long term outcome and health economic data of transplantation Organ transplantation has emerged as the gold standard therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the... ver más

31/10/2017

CHARITE UNIVERSIT...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 16 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-10-31 No tenemos la información de la convocatoria

0% 75% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

CHARITE UNIVERSITAETSMEDIZI...

0.00€ | Lider

Teva Pharmaceuticals Europe...

N.D. | Participante

KINGS COLLEGE LONDON

N.D. | Participante

ALTA SRLU

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TRANSBIO A BIOmarker based assay for prognosis and monitoring in rena... 71K€ Cerrado

EU-TRAIN The EUropean TRAnsplantation and INnovation EU TRAIN conso... 7M€ Cerrado

TRANSBIO Cellular BIOtechnology for prognosis and monitoring in renal... 4M€ Cerrado

TOLERANCE Targeting innate immunity to induce TOLERANCE in transplanta... 3M€ Cerrado

ECP TOLERANCE An Investigation into Tolerance Induction by Extracorporeal... 45K€ Cerrado

KiT-FIG Kidney Transplantation Functional ImmunoGenomics 197K€ Cerrado

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Organ transplantation has emerged as the gold standard therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the long-term success of transplantation. The paradigm is shifting from increasing net-IS by novel drugs to the concept of minimizing long-term IS as early as possible. However, data were almost completely generated by trial-and-error observational studies. It suggests an unmet need to stratify transplant (Tx) patients regarding their immunological responsiveness to the allograft and their respective individual need of IS. The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as operationally tolerant by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings–Indices of Tolerance (IOT) and RISET but also of other international groups.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores